secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiromic Biopharma, Inc. (—)
CIK:        0001792581
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001558370-22-018543
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiromic BioPharma receives Nasdaq deficiency notice for audit committee non-compliance
--------------------------------------------------------------------------------

- Frank Tirelli resigned as director effective Nov 16, 2022, leaving audit committee with fewer than 3 independent members.
- Nasdaq requires audit committee of at least 3 independent directors per Listing Rule 5605(c)(2)(A).
- Cure period until earlier of next annual shareholders' meeting or Nov 16, 2023; stock continues trading on Nasdaq.
- Board's Nominating and Corporate Governance Committee is seeking qualified candidates to fill vacancy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792581/000155837022018543/0001558370-22-018543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792581/000155837022018543/krbp-20221212x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-018543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer